Letrozole Sanoswiss (Letrozole)

Letrozole works by selectively inhibiting the aromatase enzyme, which converts androgens into estrogens. By blocking this conversion, systemic estrogen concentrations fall, depriving estrogen‑dependent cancer cells of a key growth signal and thereby slowing disease progression.

The exact dose of Letrozole is determined by the prescribing clinician based on the individual patient's condition, renal and hepatic function, and treatment goals. Physicians typically start with a standard adult dose, but adjustments are made according to therapeutic response and tolerability.

Letrozole is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To order Letrozole Sanoswiss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Letrozole, anastrozole, and exemestane are the three main aromatase inhibitors. Letrozole is a non‑steroidal, highly potent inhibitor with a long half‑life, often preferred for its consistent estrogen suppression. Anastrozole is similar but slightly less potent, while exemestane is a steroidal inhibitor with a different binding profile, which may be chosen based on patient tolerance or prior therapy.

Letrozole tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Letrozole is taken orally as a tablet, usually once daily. It can be swallowed with water and may be taken with or without food, according to the prescriber's instructions. Consistent daily dosing helps maintain steady drug levels for optimal therapeutic effect.

Serious risks include significant bone loss leading to osteoporosis or fractures, increased risk of thromboembolic events such as deep‑vein thrombosis, severe liver injury indicated by marked enzyme elevations, and rare cardiac arrhythmias. Patients should report any new bone pain, swelling, shortness of breath, or jaundice promptly.

Letrozole should not be used by pregnant or breastfeeding women, premenopausal women, patients with severe hepatic impairment, or individuals with known hypersensitivity to letrozole or any of its excipients. Clinicians must also evaluate contraindications related to bone health and cardiovascular risk before initiating therapy.